Week 9 Flashcards
HTLV-1 Spastic paraparesis causes in Peru
Infectious: syphilis, HIV (vacuolar myelopathy), TB, neurobrucellosis, HTLV-1. Non-infections: MS, familial spastic paraplegia, Konzo/lathyrism (failure to prepare cava appropriately), primary lateral sclerosis, trauma, B12 deficiency, anterior spinal thrombosis)
HTLV-1 Epidemiology
Worldwide prevalence 5-10 million carriers globally. 5-10 million carriers globally. Asymptomatic in majority (>95).
HTLV-1 Transmission
Parenteral (transfusion of cells, IVDU, solid organ transplant - high risk for HAM, prevented by screening in blood banks and organ donors), vertical & breastfeeding (rare before and during childbirth - screening/no breastfeeding if secure alternatives in place), sexual (only prevention). No proven treatment, no vaccine
HTLV-1 HAM/TSP
HTLV-1-assocated myelopathy (HAM)/Tropical spastic paraparesis (TSP); RF: women>men, aged 40-50y, genetic predisposition, high HTLV-1 provirus load. High HTLV1 Ab titres. Geographic variation ~0.25% Japan, 3% elsewhere. Discrepancy striking motor symptoms > mild sensory disturbance. Lumbar pain, bladder disorders, repeated falls due to ‘clumsy legs’ are early signs. Chronic inflammation of white and grey matter of lower thoracic spinal cord (infiltration of T cells - bystander effect/auto-antibodies followed by atrophy). Symptom progression variable phenotype of onset. Treatment limited evidence. 1g IV methylpred (3d) for symptom relief (screen Strongy, TB etc first. No role for antiviral therapy or interferon alpha. Symptomatic support: antispasmodics, laxatives, physio, secondary infections. Mortality ratio 2.25% vs main population (longevity affected).
HTLV-1 Adult systemic complications of HTLV-1
Effects of inflammation of the spinal cord (low back pain, constipation, unstable bladder, weakness). HTLV-1 associated uveitis, thyroiditis, calcium disorders, bronchiectasis, interstitial pneumonitis, eczema, seborrhoeic dermatitis, polymyositis, arthropathy, Sjogrens
HTLV-1 Infective dermatitis
Chronic relapsing erythematous lesions. Age 3-15y. Lesions of the scalp, ears, retroauricular areas, paranasal and perioral areas, neck, axillae, thorax, abdomen, groin and other sites. Lesions may be erythematous/scaly, exudative and/or crusted. Chronic, relapsing condition, prompt response to therapy, but recurrence upon discontinuation of antibiotics. Lymphadenopathy. Failure to thrive. Treatment: long-term antibiotic therapy (SXT), mild local corticosteroids for severe cases, follow up
HTLV-1 Adult T-cell leukaemia/lymphoma
HTLV-1 is a highly oncogenic virus. Median age 56y, long latency period 20-50y after HTLV1 infection. Aggressive proliferation of mature activated CD4+ CD 25+ T cells. Clinical presentation (lymphadenopathies, hepatosplenomegaly, visceral lesions), Diagnosis (‘flower cell’ on peripheral blood film = acute ATL patient-leukaemic cells with multilobulated nuclei), Complications (paraneoplastic hypercalcaemia, and opportunistic infections eg TB, strongyloidiasis)
HTLV-1 Associated infections
Crusted scabies. Strongyloidiasis - mortality 15-87%, hyperinfection risk (recurrent Gram negative sepsis, associated with normal eosinophils), associated with (larva currens, nephrotic syndrome, ARDS, chronic diarrhoea, small bowel obstruction), diagnosis (direct examination, serology), treatment: ivermectin
HTLV-1 Summary
RNA retrovirus, spread by cell-to-cell contact. 5-10 million carriers globally. Geographic foci: Japan, Latin America, Caribbean, Africa, Central Australia. Transmission: vertical, horizontal, blood products. 95% of carriers remain asymptomatic lifelong. HTLV1-associated myelopathy (HAM) or tropical spastic paraparesis. May be rapid or slow progression. Highly oncogenic virus-causing adult T-cell lymphoma/leukaemia (ATL). Systemic complications: infective dermatitis, strongyloides infection, autoimmune infections. Diagnosis: serology EIA/Western blot, Proviral PCR. Prevention: No vaccine, avoid infected bodily fluid transmission. Treatment: no proven antiviral treatment.
Anaemia Definition
A pathological condition in which the number of RBC or the Hb within them is reduced in number and unable to meet the body’s physiological oxygen-carrying needs (WHO). Anaemia is NOT a diagnosis, but a presentation of an underlying condition. WHO defines anaemia as Hb<12 in women, <13 in men
Anaemia Why is it important?
Symptomatic anaemia (reduction in cognitive function, exercise tolerance, capacity for work) Risk in children of (poor motor development, reduced cognitive function, behavioural disturbances). In pregnancy (risk of poor maternal and birth outcomes eg premature birth, low birth weight. Increased risk of maternal mortality and post-partum haemorrhage)
Anaemia Epidemiology
Burden of anaemia is maximal in sub-Saharan Africa and South Asia. At least 40% globally is secondary to iron deficiency - important as it is treatable.
Anaemia Challenges in resource-limited
Lack of/expensive investigations (haematinics [B12/folate/Fe], haemoglobinopathy diagnostics, haemolysis diagnostics [reticulocytes, LDH, haptoglobin, Coombs test], bone marrow biopsies, sometimes even FBCs). Potentially unreliable quality of lab tests (lack of quality assurance programmes)
Anaemia Pragmatic approach
Classify the anaemia (microcytic, normocytic, macrocytic - combination can cause normalisation). Think about common causes first (iron/haematinic deficiencies [consider trial of treatment], haemoglobinopathies/haemolysis, chronic disease, infections/infestations, bleeding - take a good bleeding history, including through menstrual history. Haematological cancers are much less common than all of the above - assess for other cytopenias/features of haematological disease). Blood films are really helpful, but need to be done before transfusion
Iron deficiency Assessment
Investigate and treat the underlying cause (why is the iron level low? Is there bleeding? Is there poor dietary intake? Pregnancy? Helminth infection? Chronic infection?) Assess severity of anaemia (determines treatment approach).
Iron deficiency Management options
Life-threatening/severe anaemia with haemodynamic compromise (transfuse RBC/whole blood, manage any bleeding, once patient stable, likely to need additional iron supplementation). Non-severe anaemia (oral iron supplementation, IV iron supplementation if available [helpful if surgery planned within a few weeks, lack of response to oral, malabsorption, dialysis-dependent renal disease], treat for 6 months (and min 3/12 post normalisation of FBC)
Iron deficiency When to transfuse in iron deficiency
Severe symptomatic anaemia. Transfusion has clear risks and complications. Transfuse the minimum amount of blood necessary to improve the clinical condition. Short term fix -> always aim to correct the underlying cause. Always weigh up risks vs benefits
Iron deficiency Accelerating anaemia reduction
Contributing sectors (health & nutrition, food & agriculture, water, sanitation & hygiene, education, social protection, labor, trade & industry, finance). Action areas (analyse data on causes and risk factors. Prioritise key preventive and therapeutic interventions. Optimise serve delivery across platforms and sectors. Strengthen leadership, coordination, and governance at all levels. Expand research, learning and innovation). Improve sustained, equitable and effective coverage of priority interventions for anaemia prevention, diagnosis, and treatment. Tackling the direct cause of anaemia (1 Improved micronutrient status, 2 reduced infection, inflammation, and chronic diseases, 3 reduced gynaecological and obstetric conditions (eg abnormal uterine bleeding), 4 Improved screening and management of inherited red blood cell disorders) -> optimise haemoglobin synthesis, prevent excessive destruction of red blood cells and decrease blood loss -> 2025 World Health Assembly Target 2 (achieve a 50% reduction of anaemia in women of reproductive age) -> 2030 sustainable development goals (Zero hunger (SDG2) and good health and wellbeing (SDG3), and SDG 2.2 end all forms of malnutrition)
Iron deficiency Summary
Globally anaemia is extremely common and is considered by the WHO as a serious global public health problem. Iron deficiency is by far the commonest cause. Always try to investigate and treat the underlying cause of anaemia (and the underlying cause of iron deficiency). Simple diagnostics (eg blood films) can be very helpful
Blood transfusion Epidemiology
Lack of blood contributes to 25% maternal deaths. Haemorrhage cause 10-40% of trauma deaths. Inequitable access - LMIC blood donations 5 per 1000 population per year (vs 33 per 1000 in HIC). Key points: is the transfusion definitely necessary? Is there an alternative to transfusion? Blood transfusion services are challenging and expensive - research capacity building and creating local solutions is essential.
Blood transfusion Service
Requirements (collection, processing, storage, governance), Challenges (complex and expensive, family/replacement donors, anaemia/infection prevalence, financial, socio-cultural), and Solutions (capacity building, local solutions, awareness, community centredness, regular donation schemes)
Blood transfusion Zipline
Use of drones for delivery of blood products in Rwanda -> faster delivery times, -> less blood component wastage
Blood transfusion Alternatives
Medical (haematinic replacement, antifibrinolytics eg tranexamic acid, erythrocyte stimulating agents eg erythropoietin), Surgical (cell salvage, surgical techniques to minimise blood loss)
VTE Epidemiology
VTE is estimated to cause at least 3 million deaths a year worldwide. VTE causes >40,000 deaths in Europe every year. An estimated 300,000 VTE-related deaths occur in the US each year.